Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy ...

Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the ...

U.S. stock futures ticked up Friday morning, supported by a mostly upbeat earnings season even as several major names posted ...

Stock futures nudged higher on Friday, driven by strong performances from major technology companies and growing optimism over potential trade agreements ahead of the Trump administration’s August ...